Stock Track | BIOCYTOGEN-B Soars 5.39% Intraday on Partner's FDA IND Clearance for Bispecific ADC

Stock Track03-27

BIOCYTOGEN-B's stock price soared 5.39% during intraday trading on Friday, reflecting significant investor interest.

The surge follows news that the company's partner, NEOK Bio, Inc., has received Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) for its bispecific antibody-drug conjugate (ADC) candidate, NEOK002. This drug, intended for treating solid tumors, is built upon a bispecific antibody originally developed by BIOCYTOGEN-B.

The achievement marks a critical milestone for the collaborative project and validates the potential of BIOCYTOGEN-B's proprietary RenLite® antibody platform. Company leadership highlighted this as evidence of the platform's strength in developing innovative therapeutics with clinical translation potential.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1108242718?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-27 09:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1108242718","market":"sg","top_or_hot":-1,"title":"Stock Track | BIOCYTOGEN-B Soars 5.39% Intraday on Partner's FDA IND Clearance for Bispecific ADC","media":"Stock Track","content":"<p>BIOCYTOGEN-B's stock price soared 5.39% during intraday trading on Friday, reflecting significant investor interest.</p><p>The surge follows news that the company's partner, NEOK Bio, Inc., has received Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) for its bispecific antibody-drug conjugate (ADC) candidate, NEOK002. This drug, intended for treating solid tumors, is built upon a bispecific antibody originally developed by BIOCYTOGEN-B.</p><p>The achievement marks a critical milestone for the collaborative project and validates the potential of BIOCYTOGEN-B's proprietary RenLite® antibody platform. Company leadership highlighted this as evidence of the platform's strength in developing innovative therapeutics with clinical translation potential.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | BIOCYTOGEN-B Soars 5.39% Intraday on Partner's FDA IND Clearance for Bispecific ADC</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | BIOCYTOGEN-B Soars 5.39% Intraday on Partner's FDA IND Clearance for Bispecific ADC\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-03-27 09:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>BIOCYTOGEN-B's stock price soared 5.39% during intraday trading on Friday, reflecting significant investor interest.</p><p>The surge follows news that the company's partner, NEOK Bio, Inc., has received Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) for its bispecific antibody-drug conjugate (ADC) candidate, NEOK002. This drug, intended for treating solid tumors, is built upon a bispecific antibody originally developed by BIOCYTOGEN-B.</p><p>The achievement marks a critical milestone for the collaborative project and validates the potential of BIOCYTOGEN-B's proprietary RenLite® antibody platform. Company leadership highlighted this as evidence of the platform's strength in developing innovative therapeutics with clinical translation potential.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02315","symbol_name":"百奥赛图-B","start_time":0,"source_url":"","article_id":"1108242718","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1108242718","pubTimestamp":1774576729,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"BIOCYTOGEN-B's stock price soared 5.39% during intraday trading on Friday, reflecting significant investor interest.The surge follows news that the company's partner, NEOK Bio, Inc., has received...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02315":"百奥赛图-B"},"translate_title":"个股追踪|合作伙伴双特异性ADC获FDA IND批准生物奥赛图-B盘中大涨5.39%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02315":1},"content_text":"BIOCYTOGEN-B's stock price soared 5.39% during intraday trading on Friday, reflecting significant investor interest.The surge follows news that the company's partner, NEOK Bio, Inc., has received Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) for its bispecific antibody-drug conjugate (ADC) candidate, NEOK002. This drug, intended for treating solid tumors, is built upon a bispecific antibody originally developed by BIOCYTOGEN-B.The achievement marks a critical milestone for the collaborative project and validates the potential of BIOCYTOGEN-B's proprietary RenLite® antibody platform. Company leadership highlighted this as evidence of the platform's strength in developing innovative therapeutics with clinical translation potential.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1108242718","isCrawlerRequest":true}